**EXHIBIT      10.29**

----

----

**CONVERTIBLE      NOTE AND WARRANT PURCHASE AGREEMENT**

----

**CONVERTIBLE      NOTE AND WARRANT PURCHASE AGREEMENT**
*Agreement*
*Company*
*Purchaser*
*Purchasers*

*Notes*
*Warrants*
** **

**ARTICLE      I**

**DEFINITIONS      AND TERMS OF NOTES AND WARRANTS**

**1.1**
**Definitions**

*Action*

*Affiliate*

*Agreement*

*Business      Day*

*Closing*

*Closing      Date*

*Commission*

*Common      Stock*

----

*Common      Stock Equivalents*

*Company*

*Conversion      Shares*

*Disclosure      Schedules*

*Effective      Date*

*Environmental      Laws*

*Exchange      Act*

*FDC      Act*

*February      Notes*

*February      Purchase Agreement*

*GAAP*

*Governmental      Authorizations*

*Hazardous      Substances*

*Indemnified      Party*

*Indemnifying      Party*

*Intellectual      Property*

*Investor      Rights Agreement*

*Lien*

----

*Material      Adverse Effect*

*Notes*

*October      Notes*

*October      Purchase Agreement*

*Person*

*Placement      Agent Warrants*

*Premises*

*Purchaser*

*Registration      Statement*

*Rights*

*Rule      144*

*SEC      Reports*

*“Second      Security Agreement Amendment”*

*Securities*

----

*Securities      Act*

*“Security      Agreement”*

*“Security      Agreement Amendment”*

*Subscription      Amount*

*Subsidiary*

*Trading      Day*

*Trading      Market*

*Transaction      Documents*

*Warrants*

*Warrant      Shares*

**1.2**
**Terms      of the Notes and Warrants**
**.**

----

**ARTICLE      II**

**PURCHASE      AND SALE**

**2.1**
**Closing**
**.**

*Closing*
*Closing      Date*

** **
*Escrow      Agent*
*Closing      Escrow Agreement*

**2.2**
**Conditions      to Obligations of Purchasers to Effect the Closing**

----

** **

*Secretary’s      Certificate*

**2.3.**
**Conditions      to Obligations of the Company to Effect the Closing**

----

**ARTICLE      III**

**REPRESENTATIONS      AND WARRANTIES**

**3.1**
**Representations      and Warranties of the Company**

**(a)      **
**Subsidiaries**

**(b)      **
**Organization      and Qualification**
*Material      Adverse Effect*

**(c)      **
**Authorization;      Enforceability**

**(d)      **
**No      Conflicts**

----

**(e)      **
**Filings,      Consents and Approvals**

**(f)      **
**Issuance      of the Securities**

**(g)      **
**Capitalization**

----

**(h)**
**SEC      Reports; Financial Statements; Liabilities**

*SEC      Reports*

*GAAP*

----

**(i)      **
**Material      Changes**

----

**(j)      **
**Litigation**
*Action*

**(k)      **
**Labor      Relations**

**(l)      **
**Compliance**

----

**(m)      **
**Licenses;      Compliance With FDA and Other Regulatory Requirements.**

*Governmental      Authorizations*

*FDC      Act*
*Regulatory      Authority*

**(n)      **
**Title      to Assets**

----

**(o)**
**Intellectual      Property. **

*Rights*
*Intellectual      Property*

**(p)**
**Insurance**

----

**(q)**
**Transactions      With Affiliates and Employees**

**(r)      **
**Internal      Accounting Controls**

**(s)      **
**Certain      Fees**

**(t)      **
**Private      Placement; Integrated Offering**

----

**(u)      **
**Charter,      Bylaws and Corporate Records.**

**(v)      **
**Registration      Rights**

**(w)      **
**Listing      and Maintenance Requirements**

**(x)**
**Taxes.      **

----

**(y)**
**Environmental      Matters. **
*Premises*
*Hazardous      Substances*
*Environmental      Laws*

**(z)      **
**Disclosure**

----

**(aa)**
**No      Additional Representations.**

**(bb)      Poison Pill.**

**3.2      **
**Representations      and Warranties of the Purchasers**
**.      **

**(a)      **
**Organization;      Authority; Enforceability**

**(b)      **
**General      Solicitation**

**(c)      **
**No      Public Sale or Distribution**
*provided,      however*

----

**(d)      **
**Accredited      Investor Status**

**(e)      **
**Residency**
** **

**(f)      **
**Reliance      on Exemptions**

**(g)      **
**Information**

**(h)      **
**No      Governmental Review**

**(i)      **
**Experience      of Such Purchaser**

----

**ARTICLE      IV**

**OTHER      AGREEMENTS OF THE PARTIES**

**4.1**
**Transfer      Restrictions**
**.**

*      provided, however*
** **

*SECURITIES      ACT*

----

*ACCREDITED      INVESTOR*

----

**4.2      **
**Furnishing      of Information**
**.      **

**4.3**
**Integration**
**.**

**4.4**
**Publicity**
**.      **

----

**4.5**
**Use      of Proceeds**
**.**

**4.6**
**Reservation      of Common Stock**
**.**

**4.7**
**Listing      of Common Stock**
**.**

**4.8**
**Business      Operations**
**.**

**(a)**
**Insurance**

----

**(b)**
**Corporate      Existence; Licenses.**

**(c)**
**Taxes      and Claims.**

**(d)**
**Affiliate      Transactions**

**4.9**
**Securities      Law Compliance**

**(a)**
**Securities      Act**

**(b)**
**State      Securities Law Compliance -- Sale**

**(c)**
**State      Securities Law Compliance --Resale**

----

**4.10      **
**Poison      Pill**
**.**

**4.11**
**Director      Designees**
**.      **

**ARTICLE      V**

**INDEMNIFICATION,      TERMINATION AND DAMAGES**

**5.1**
**Survival      of Representations**
**.**

**5.2**
**Indemnification**
**.      **

----

*provided,      however*

**5.3**
**Indemnity      Procedure**
**.**

*Indemnifying      Party*
*Indemnified      Party*
*provided,      however*

----

**ARTICLE      VI**

**MISCELLANEOUS**

**6.1**
**Fees      and Expenses**
**.**

**6.2**
**Entire      Agreement**
**.**

**6.3**
**Notices**
**.**

----

**6.4**
**Amendments;      Waivers**

**6.5**
**Construction**
**.**

----

**6.6**
**Successors      and Assigns**
**.**

**6.7**
**No      Third-Party Beneficiaries**
**.**

**6.8**
**Governing      Law.**

**6.9      **
**Jurisdiction;      Venue; Service of Process**
**.**

**6.10      **
**Execution**
**.**

----

**6.11      **
**Severability**
**.**

**6.12**
**Replacement      of Securities**
**.**

**6.13      **
**Remedies**
**.**

**6.14**
**Payment      Set Aside**
**.**

**6.15**
**Independent      Nature of Purchasers’ Obligations and Rights**
**.      **

----

**6.16**
**Waiver      of Trial by Jury**
**.**

**6.17**
**Further      Assurances**
**.**

*[Signature      pages follow.]*

----

**COMPANY:**

**ACCESS      PHARMACEUTICALS, INC.**

----

**PURCHASERS:**

|                                       | Print Exact     |  Name:                                      | SCO                  Capital Partners LLC  |
|--------------------------------------------|-----------------|--------------------------------------------------|-------------------------------------------------|
|                                       |            |
|         | By:             |                                                  |  /s/                Steven H. Rouhandeh    |
|                                       | Name:           |  Steven H. Rouhandeh                        |
|                                       | Title           |                                                  |  Chairman                                  |
|                                       |                 |                                             |
|                                       | Address:        |  1285                Avenue of the Americas |
|                                       |                 |  35th                Floor                  |
|                                       |                 |  New                York, NY 10019          |
|                                       | Telephone:      |  212-554-4158                               |
|                                       | Facsimile       |  212-554-4058                               |
|                                       |  Email     |                              |
|                                       |  SSN/EIN   |  52-2247879                                 |
|                                       |  Amount of | Investment $                                     | 400,000.00                                      |

----

**PURCHASERS:**

|                                       | Print Exact     |  Name:                                  | Lake                End Capital LLC  |
|--------------------------------------------|-----------------|----------------------------------------------|-------------------------------------------|
|                                       |            |
|         | By:             |                                              |  /s/              Jeffrey B. Davis   |
|                                       | Name:           | Jeffrey B. Davis                             |
|                                       | Title           |                                              |  Chairman                            |
|                                       |                 |                                         |
|                                       | Address:        | 33              Tall              Oaks Drive |
|                                       |                 |  Summit,              NJ 07901          |
|                                       |                 |                                         |
|                                       | Telephone:      |  212-554-4158                           |
|                                       | Facsimile       |  212-554-4058                           |
|                                       |  Email     |  jdavis@scogroup.com                    |
|                                       |  SSN/EIN   |  20-2334991                             |
|                                       |  Amount of | Investment $                                 | 100,000.00                                |

----